The FinancialContent Network     SocialPicks Community   |   MarketMinute Monitor   |   MarketMinute Market Updates   |   MarketMinute Stock News
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
1 pt

Opinion on  Pharmacyclics Inc. (PCYC)     Sector: Healthcare  >  Industry: Biotechnology & Drugs
PCYC CEO confident of approval

May 31, 2007 02:30 PM GMT
Lotus170107
Return Risk
+52.88% HIGH
Sr. Analyst

Recent News  

The stage is now set for Pharmacyclics to finally be heard by the FDA.  With Dendreon breaking the mold at the FDA the stage is now set for approval of Xcytrin.    The CEO is urging the FDA to assemble a panel and review the drug for approval in June.

PCYC:  This call was made on 05/31/07 @ $3.07
Rating:   Positive   $3.07 (05/31/07)
Gain/Loss:   +964.82% in 1824 days
Target:   $15.00 (+388.60%) in > one year


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 21.10 +34.36% 531
2 Gerald Greene 18.14 +36.28% 286
3 stockmarketfunding.com 17.66 +23.07% 83
4 akiralegrand 13.47 +13.37% 69
5 anup2104 12.13 +132.16% 102


POPULAR STOCKS
Symbol Company Name Sentiment
DELL Dell Inc
C Citigroup Inc
CHL China Mobile Ltd
YHOO Yahoo! Inc
HPQ HewlettPackard Company
CSCO Cisco Systems Inc

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
Pharmacyclics Inc. (PCYC)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
100.0%
Top:
0.0%




Latest Picks by Aircarp
Symbol SP Sentiment Rating Return Since
CAMH N/A Positive n/a 04/20/10
MGRM Positive n/a 06/18/07
DNDN Positive -13.29% 05/31/07
NGNM N/A Positive n/a 04/20/07

View All >
   
Aircarp previously rated PCYC
Negative +1.52% FDA files NDA for Pharmacyclics drug Xcytrin
04/23/2007
6
Positive +19.27% Pharmacyclics Challenges FDA
04/04/2007
37





IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch